The Goldman Sachs Group Inc Reaffirms Buy Rating for GlaxoSmithKline plc (GSK)

The Goldman Sachs Group Inc Reaffirms Buy Rating for GlaxoSmithKline plc (GSK)

GSK has been the subject of a number of other research reports. Credit Suisse Group AG reaffirmed a neutral rating and set a GBX 1,750 ($22.48) target price on shares of GlaxoSmithKline plc in a report on Thursday, March 2nd. Deutsche Bank AG reaffirmed a hold rating and set a GBX 1,720 ($22.09) target price on shares of GlaxoSmithKline plc in a report on Friday, March 31st. JPMorgan Chase & Co. reaffirmed a neutral rating and set a GBX 1,750 ($22.48) target price on shares of GlaxoSmithKline plc in a report on Saturday, May 20th. Beaufort Securities reaffirmed a buy rating and set a GBX 1,750 ($22.48) target price on shares of GlaxoSmithKline plc in a report on Friday, February 10th. Finally, Berenberg Bank set a GBX 1,890 ($24.28) target price on GlaxoSmithKline plc and gave the company a neutral rating in a report on Monday, March 20th. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus price target of GBX 1,751.77 ($22.50).

Goldman Sachs Group Inc restated their buy rating on shares of GlaxoSmithKline plc (LON:GSK) in a report released on Wednesday. The brokerage currently has a GBX 1,900 ($24.41) price objective on the stock.

Shares of GlaxoSmithKline plc (LON:GSK) opened at 1695.0664 on Wednesday. GlaxoSmithKline plc has a 52-week low of GBX 1,363.00 and a 52-week high of GBX 1,745.56. The company’s 50-day moving average is GBX 1,620.99 and its 200 day moving average is GBX 1,592.49. The company’s market cap is GBX 82.82 billion. The company also recently announced a dividend, which will be paid on Thursday, July 13th. Investors of record on Thursday, May 11th will be given a GBX 19 ($0.24) dividend. The ex-dividend date of this dividend is Thursday, May 11th. This represents a yield of 1.21%.

In other news, insider Dominic Redfern bought 230 shares of the company’s stock in a transaction that occurred on Thursday, April 13th. The stock was bought at an average price of GBX 1,639 ($21.05) per share, for a total transaction of £3,769.70 ($4,842.26). Also, insider Vivienne Cox bought 335 shares of the company’s stock in a transaction that occurred on Wednesday, April 26th. The stock was purchased at an average price of GBX 1,583 ($20.33) per share, with a total value of £5,303.05 ($6,811.88). Insiders purchased a total of 718 shares of company stock valued at $1,183,024 in the last 90 days. GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “LSE:GSK”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment